Clinical factors associated with early progression and grade 3–4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab
Year: 2018
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: The prognosis of advanced non-small-cell lung cancer (NSCLC) has been improved by development of immune checkpoint inhibitors (ICIs) such as nivolumab for second-line treatment. As phase III trials include only selected patients, we here investigated the clinical factors associated with efficacy and safety of nivolumab in 'real life' patients with advanced NSCLC. METHODS: Clinical and histological characteristics, therapies and survival data of all consecutive patients with advanced NSCLC included prospectively and treated by nivolumab in two French academic hospitals between February 2015 and December 2016 were examined. RESULTS: Sixty-seven patients were included, mostly male (69%), current or former smokers (87%) with PS <2 (73%). Median age was 68.5 years and 42% were aged ≥70 years. According to uni- and multi-variate analyses, only PS 2 (OR = 0.17, 95% CI 0.03-0.99, p = 0.049) and number of previous treatment lines (OR = 0.33, 95% CI 0.13-0.85, p = 0.022) were significantly negatively associated with tumor control. Worse progression-free survival (PFS) was significantly associated with PS 2 (HR = 5.17, 95% CI 1.99-13.43, p = 0.001) and use of steroids (HR = 3.27, 95% CI 1.39-7.69, p = 0.006). Worse overall survival was associated with symptomatic brain metastasis (HR = 3.15, 95% CI 1.23-8.85, p = 0.029). Treatment-related adverse events occurred in 47 patients (70%), symptomatic brain metastasis being significantly associated with Grade ≥3 toxicity (OR = 8.13, 95% CI 1.21-55.56, p = 0.031). Age and nutritional status were not associated with response, PFS, OS or toxicity. CONCLUSION: Our results suggest that nivolumab is not beneficial or safe for patients with PS 2 and symptomatic brain metastases.
Source: PLoS ONE
Authors: Coraline Dumenil(Conceptualization, Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing), Marie-Ange Massiani(Data curation, Writing – review & editing), Jennifer Dumoulin(Writing – review & editing), Violaine Giraud(Writing – review & editing), Sylvie Labrune(Writing – review & editing), Thierry Chinet(Supervision, Validation, Writing – review & editing), Etienne Giroux Leprieur(Conceptualization, Formal analysis, Methodology, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: nivolumab, non-small cell lung cancer, immune checkpoint inhibitors, second-line therapy, prognostic factors, performance status, brain metastases, progression-free survival, overall survival, treatment-related adverse events, corticosteroid use, real-world outcomes, tumor control, predictive biomarkers, PD-1 inhibitors, immunotherapy safety and efficacy
Open Access status: gold
Estimated APC paid: $1,612
OpenAlex ID: W2799511849
